The device is expected to be used with Genedrive's hepatitis C virus assay, which recently received CE-IVD marking.
As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
Eleven sites have been established across Britain to enable the development of new tests and technologies within the UK National Health Service, as well as to evaluate commercial IVD kits.
Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.
The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.